Clear Cell Myomelanocytic Tumor of the Urinary Bladder

Pan, Chin-Chen; Yu, I-Ting; Yang, An-Hang; Chiang, Hung

doi:10.1097/00000478-200305000-00013

Cited by 75 publications

(54 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first report by Pan and colleagues described a 33-year-old Taiwanese woman who was found to have a PEComa of the bladder during a workup for dysmenoorhea. 8 The patient did not have any lower urinary tract symptoms or gross hematuria. She underwent partial cystectomy with total excision of the tumour and remained without evidence of disease with 6 years of follow-up.…”

Section: Discussionmentioning

confidence: 86%

“…6 PEComas have been documented in a variety of anatomical locations, including the pancreas, small and large intestine, ligamentum teres/falciform ligament, common bile duct, kidney, bladder, prostate, breast, uterus, cervix, vulva, ovary, broad ligament, heart, base of skull and soft tissue. 8,[12][13][14][15] The major differential diagnosis of this tumour around the anatomical site of the urinary bladder, includes smooth muscle tumours. Smooth muscle tumours, including leiomyoma and leiomyosarcoma, are the most common mesenchymal tumours of the urinary bladder in adults.…”

Section: Discussionmentioning

confidence: 99%

“…3,7 Currently in the literature there are only 3 reported cases of PEComas originating in the urinary bladder. [8][9][10] We report the diagnosis, management and short-term follow-up of the fourth documented case of primary PEComa of the urinary bladder. In addition, we report the first case of this tumour managed by partial cystectomy performed laparoscopically.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clear cell myomelanocytic tumour: minimally invasive treatment of a rare bladder tumour

Pianezza

Slatnik

Evans

2013

CUAJ

View full text Add to dashboard Cite

Clear cell myomelanocytic tumours are extremely rare neoplastic growths considered to be members of the family of perivascular epithelioid cell tumours (PEComas), which have in common the coexpression of melanocytic and smooth muscle immunohistochemical markers. These tumours are known to be ubiquitous with uncertain tumour biology and to have unpredictable clinical behaviour. They have been reported in the genitourinary tract, including the kidney and prostate. There are only 3 reported cases of clear cell myomelanocytic tumours originating in the urinary bladder. We report a case of a 24-year-old woman with chronic pelvic pain who underwent laparoscopic partial cystectomy and total excision of a bladder mass. Pathological examination revealed primary PEComa of the urinary bladder. Subsequent follow-up procedures, including cystoscopy and imaging, have not revealed any evidence of disease recurrence. The patient remains clinically free of disease 3 months after surgery.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clear cell myomelanocytic tumour: minimally invasive treatment of a rare bladder tumour

Pianezza

Slatnik

Evans

2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…This lack of criteria is primarily a result of the tumour's rarity and the limited follow-up reported in most cases 12,17,18 . The limited number of malignant cases published thus far have described malignant spread as being characterized by a locally infiltrative growth pattern, vascular invasion, a high mitotic rate, necrosis, and tumour size exceeding 8 cm 4,14,16,[19][20][21][22] . The clinical behaviour of pecomas is generally benign.…”

Section: Discussionmentioning

confidence: 99%

PEComa of the Terminal Ileum Mesentery as a Secondary Tumour in an Adult Survivor of Embryonal Rhabdomyosarcoma

et al. 2015

View full text Add to dashboard Cite

Perivascular epithelioid cell tumours (pecomas) are rare mesenchymal tumours that are characterized by perivascular epithelioid cell differentiation and immunoreactivity to myogenic and melanocytic markers. These tumours can be classified as benign, uncertain malignant potential, or malignant. Because of the rarity of pecomas, their cause and clinical prognosis remain unclear.To the best of our knowledge, no reports in the literature describe a pecoma of the terminal ileum mesentery as a secondary tumour in an adult survivor of childhood embryonal rhabdomyosarcoma, let alone any childhood cancer. Here, we present the case of a 27-year-old man with a pecoma involving the mesentery of the terminal ileum. At the age of 5, he had been treated with a combination of chemotherapy and high-dose pelvic radiation therapy for embryonal rhabdomyosarcoma, most likely arising from the posterior bladder wall.During routine follow-up 22 years after this patient's initial treatment, computed tomography imaging revealed a mass within the terminal ileum mesentery. The tumour was successfully treated with surgical resection, and pathology examination determined the mass to be a pecoma with uncertain malignant potential.This first case of a pecoma of the terminal ileum mesentery arising within a high-dose radiation therapy field as a secondary tumour in an adult survivor of childhood cancer highlights the importance of screening and surveillance in high-risk childhood cancer survivors treated with high-dose radiation therapy. Further research to build a better understanding of this remarkably rare tumour is warranted.

show abstract

“…The perivascular myoid cell concept has yielded the recognition of myopericytoma [3][4][5][6][7][8], myofibroma [4], myofibromatosis [9], angioleiomyoma [10], and glomus tumors (GTs) [9,11,12], while the perivascular epithelioid cell concept that shows melanocytic lineage has led to the recognition of PEComa [13,14], clear cell sugar tumor [15,16], angiomyolipoma [17], and lymphangiomyomatosis [1]. These tumors belong to a spectrum of perivascular myoid cell tumors and perivascular epithelioid cell tumors, and there are some overlaps among these entities.…”

Section: Introductionmentioning

confidence: 99%

Malignant glomus tumor of the foot with obvious neuroendocrine differentiation: a with immunohistochemical studies

Terada¹

2014

pjp

View full text Add to dashboard Cite

Obvious neuroendocrine differentiation has not been reported in glomus tumor. The author herein reports a malignant glomus tumor of the foot showing obvious neuroendocrine differentiation. A 63-year-old woman presented with tumor of the left foot. The tumor was superficially seated, and located in the dermis. It was completely resected with wide margins. It measured 0.7 × 0.7 × 0.6 cm. Microscopically, the tumor was composed of atypical epithelioid cells located around blood vessel-like structures. The epithelioid cells showed relatively clear cytoplasm and severe cellular atypia, and resembled basal cell carcinoma. Focal areas of squamoid differentiation, carcinoid patterns, and neural differentiations were seen. There was no necrosis or atypical mitosis. However, mitotic figures were seen in 16 per 50 high-power-fields (HPF). The hematoxylin and eosin (HE) diagnosis was basosquamous carcinoma. Immunohistochemically, the tumor cells were strongly positive for vimentin, α-smooth muscle actin, and neuron-specific enolase. The tumor was focally positive for NCAM, synaptophysin and chromogranin. The blood vessel-like structures had a layer of CD31-and CD34-positive endothelial cells. Tp53 was positive and the Ki-67 labeling index was 23%. The tumor cells were negative for cytokeratin (CK) AE1/3, CK CAM5.2, CK5, CK6, CK7, CK8, CK14, CK18, CK19, CK20, p63, EMA, CEA, CA19-9, desmin, myoglobin, HMB-45, Melan-A, S100 protein, MUC1, MUC2, MUC5AC, and MUC6. Taken together with HE histology, the tumor was labeled as malignant glomus tumor with neuronal differentiation, based on the classification system of Folpe et al. The post-pathological diagnosis whole body examination using CT, MRI, PET, and endoscopies identified no tumors. The patient is now free from tumor and healthy 18 months after the resection.

show abstract

Clear Cell Myomelanocytic Tumor of the Urinary Bladder

Cited by 75 publications

References 22 publications

Clear cell myomelanocytic tumour: minimally invasive treatment of a rare bladder tumour

Clear cell myomelanocytic tumour: minimally invasive treatment of a rare bladder tumour

PEComa of the Terminal Ileum Mesentery as a Secondary Tumour in an Adult Survivor of Embryonal Rhabdomyosarcoma

Malignant glomus tumor of the foot with obvious neuroendocrine differentiation: a with immunohistochemical studies

Contact Info

Product

Resources

About